Aveanna Healthcare (NASDAQ:AVAH) Major Shareholder Robert Williams, Jr. Sells 2,250,000 Shares

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder Robert Williams, Jr. sold 2,250,000 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $11.50, for a total transaction of $25,875,000.00. Following the completion of the sale, the insider owned 12,315,892 shares in the company, valued at $141,632,758. This represents a 15.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aveanna Healthcare Trading Up 4.1%

Shares of Aveanna Healthcare stock opened at $13.70 on Tuesday. The company has a debt-to-equity ratio of 4.47, a current ratio of 1.16 and a quick ratio of 1.16. Aveanna Healthcare Holdings Inc. has a 1 year low of $5.93 and a 1 year high of $13.98. The company has a market capitalization of $2.99 billion, a P/E ratio of 11.14, a P/E/G ratio of 0.92 and a beta of 1.90. The business has a 50 day moving average price of $9.71 and a 200 day moving average price of $7.95.

Aveanna Healthcare (NASDAQ:AVAH) last posted its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.17 by $0.05. The firm had revenue of $670.48 million for the quarter, compared to analyst estimates of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. Sell-side analysts anticipate that Aveanna Healthcare Holdings Inc. will post 0.68 EPS for the current fiscal year.

More Aveanna Healthcare News

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Royal Bank of Canada raised its price target from $10 to $16 and upgraded its rating to “outperform,” implying additional upside from the stock’s recent trading level. Benzinga analyst coverage
• Positive Sentiment: Truist Financial lifted its price target from $11 to $15 while maintaining a “hold” rating. The higher target reflects improved valuation expectations, even though Truist remains cautious on the shares. Benzinga analyst coverage
• Negative Sentiment: Insiders and major shareholders disclosed approximately 48.6 million shares of sales at an average price of $11.50, worth roughly $558.5 million. Sellers included Paul R. Vigano, Robert M. Williams Jr., and J.H. Whitney Equity Partners V, as well as CEO Jeff Shaner, director Rodney D. Windley, and insider Edwin C. Reisz. Although the sellers retained sizable positions, the volume of stock coming to market may pressure AVAH and raise questions about shareholder confidence. SEC insider transaction filing

Wall Street Analysts Forecast Growth

AVAH has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Thursday, July 2nd. Royal Bank Of Canada boosted their price objective on shares of Aveanna Healthcare from $10.00 to $16.00 and gave the stock an “outperform” rating in a research note on Monday. Wall Street Zen lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 15th. Raymond James Financial raised their target price on Aveanna Healthcare from $13.00 to $15.00 and gave the company a “strong-buy” rating in a report on Friday, August 14th. Finally, Barclays boosted their price objective on shares of Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a report on Thursday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.89.

Institutional Investors Weigh In On Aveanna Healthcare

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd raised its stake in Aveanna Healthcare by 252.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after buying an additional 2,400 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Aveanna Healthcare in the 2nd quarter worth approximately $43,000. Summit Securities Group LLC bought a new stake in shares of Aveanna Healthcare in the 1st quarter valued at approximately $53,000. Oxford Asset Management LLP bought a new stake in shares of Aveanna Healthcare in the 2nd quarter valued at approximately $64,000. Finally, C M Bidwell & Associates Ltd. acquired a new stake in shares of Aveanna Healthcare during the 2nd quarter valued at approximately $69,000. Institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.